Assessment of Preclinical Target Organ Damage in Hypertension

Assessment of Preclinical Target Organ Damage in Hypertension

 In the natural history of hypertension, the compensatory increase in left ventricular mass ceases to be beneficial. Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. In addition to elevated BP, several mechanisms are involved, including body size, age, gender, race, fibrogenic cytokines, and neurohumoral factors, notably angiotensin II, which favor interstitial collagen deposition and perivascular fibrosis. These tissue changes are responsible for the insidious contractile dysfunction that is associated with LVH, consequent to decreased coronary reserve and altered diastolic ventricular filling and relaxation. The cardinal investigations are echocardiography and electrocardiography. All antihypertensive drugs regress LVH, notably those that act on the renin-angiotensin-aldosterone system, which also could target the detrimental tissue changes. Regression enhances systolic midwall performance, normalizes autonomic function, and restores coronary reserve.

    Related Conference of Assessment of Preclinical Target Organ Damage in Hypertension

    March 18-19, 2026

    15th World Heart Congress

    Paris, France
    March 23-24, 2026

    37th Annual Cardiologists Conference

    London, UK
    March 23-24, 2026

    13th International Conference on Hypertension and Cardiovascular Diseases

    London, UK
    March 23-24, 2026

    41st World Cardiology Conference

    London, UK
    March 26-27, 2026

    13th International Conference on Interventional Cardiology

    London,
    April 06-07, 2026

    40th World Congress on Heart Diseases

    Paris, France
    April 08-29, 2026

    9th Annual Heart Rhythm Conference

    Vienna, Austria
    April 13-14, 2026

    9th World Heart and Brain Conference

    Tokyo, Japan
    April 15-16, 2026

    8th World Heart Congress

    Tokyo, Japan
    April 29-30, 2026

    6th World Congress on Congestive Heart Failure & Angina

    Paris, France
    May 14-15, 2026

    5th International Conference on Cardiology

    Rome, Italy
    May 21-22, 2026

    13th World Congress on Hypertension, Cardiology, Primary Health and Patient Care

    Paris, France
    May 21-22, 2026

    15th World Congress on Cardiology

    London, UK
    June 15-16, 2026

    7th International Conference on Cardiac Imaging and Diagnostics

    Paris, France
    June 15-16, 2026

    7th European Summit on Cardiology Research

    Zurich, Switzerland
    July 23-24, 2026

    13th International Conference on Geriatric Cardiology, Cardiovascular Diseases and Palliative Care

    Paris, France
    July 27-28, 2026

    9th International Conference on Cardiovascular Diseases and Therapeutics

    Amsterdam, Netherlands
    July 29-30, 2026

    30th World Cardiology Conference

    Paris, France
    August 17-18, 2026

    4th International Conference on World Heart Care

    Toronto, Canada
    August 24-25, 2026

    15th World Heart Congress

    London, UK
    August 27-28, 2026

    40th European Cardiology Conference

    Berlin, Germany
    October 22-23, 2026

    34th International Congress on Cardiology and Medical Interventions

    Toronto, Canada
    November 09-10, 2026

    9th Global Cardiovascular Research and Clinical Cardiology

    Paris, France
    November 25-26, 2026

    33rd World Heartcare Summit

    Paris, France

    Assessment of Preclinical Target Organ Damage in Hypertension Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in